{"id":8460,"date":"2025-09-28T14:30:05","date_gmt":"2025-09-28T14:30:05","guid":{"rendered":"https:\/\/polikistikover.net\/yeni\/?page_id=8460"},"modified":"2025-11-25T22:56:20","modified_gmt":"2025-11-25T22:56:20","slug":"polikistik-over-sendromu-ve-kan-basinci-yuksekligi-hipertansiyon","status":"publish","type":"page","link":"https:\/\/polikistikover.net\/yeni\/polikistik-over-sendromu-ve-kan-basinci-yuksekligi-hipertansiyon\/","title":{"rendered":"Polikistik Over Sendromu ve Kan Bas\u0131nc\u0131 Y\u00fcksekli\u011fi (Hipertansiyon)"},"content":{"rendered":"\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">Kalp ve damar hastal\u0131\u011f\u0131&nbsp;(kalp, beyin ve bacaklara oksijen ta\u015f\u0131yan damarlar\u0131n t\u0131kanmas\u0131 veya daralmas\u0131) ihtimalini artt\u0131ran \u00f6zelliklerden bir tanesi kan bas\u0131nc\u0131 y\u00fcksekli\u011fi (hipertansiyon) dir.<\/mark><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-blue-color\">Bu \u00f6zelliklerden en az 3 tanesi&nbsp;biraraya gelerek metabolik sendromu olu\u015fturmaktad\u0131r(1,2,3,4);<\/mark><\/strong><\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f90908\" class=\"has-inline-color\">1-<\/mark><\/strong>Kan bas\u0131nc\u0131 y\u00fcksekli\u011fi (\u2265 130 \/85 mmHg)<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f70404\" class=\"has-inline-color\">2-<\/mark><\/strong>V\u00fccudun \u00fcst k\u0131sm\u0131nda yani kar\u0131n ve bel b\u00f6lgesinde&nbsp;bulunan ya\u011f miktar\u0131n\u0131n artmas\u0131 (bel \u00e7evresi&nbsp;\u2265 80 cm)<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#fd2208\" class=\"has-inline-color\">3-<\/mark><\/strong>A\u00e7l\u0131k kan \u015fekeri (glukoz) y\u00fcksekli\u011fi (\u2265 100 mg\/dL)<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f41209\" class=\"has-inline-color\">4-<\/mark><\/strong>Kan ya\u011flar\u0131ndan faydal\u0131 olan HDL-C miktar\u0131n\u0131n azalmas\u0131 (\u2264 50 mg\/dL)<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#fa0404\" class=\"has-inline-color\">5-<\/mark><\/strong>Kan ya\u011flar\u0131ndan trigliserid miktar\u0131n\u0131n artmas\u0131 (&nbsp;\u2265150 mg\/dL)<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">Polikistik over sendromu olan kad\u0131nlarda metabolik sendrom daha s\u0131k g\u00f6r\u00fclmektedir.(5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29).<\/mark><\/strong><\/p>\n\n\n\n<p>Kalp ve damar hastal\u0131\u011f\u0131 ihtimalini artt\u0131ran metabolik sendrom\u2019un \u00f6zelliklerden biri de kan bas\u0131nc\u0131n\u0131n y\u00fcksek&nbsp;(130 \/80 mmHg) olmas\u0131d\u0131r(30,31).<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">Polikistik over sendromu olan kad\u0131nlarda kan bas\u0131nc\u0131 y\u00fcksekli\u011fi s\u0131k g\u00f6r\u00fclmektedir(30,31,32).<\/mark><\/strong><\/p>\n\n\n\n<p><strong><mark style=\"background-color:#ebf90a\" class=\"has-inline-color\">1-<\/mark><\/strong>Bu kad\u0131nlarda kan bas\u0131nc\u0131n\u0131 en \u00e7ok ins\u00fclin direnci etkilemektedir(33).<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f6fb05\" class=\"has-inline-color\">2-<\/mark><\/strong>Erkeklik hormonlar\u0131n\u0131n (androgen) etkisinin fazla olmas\u0131 (hiperandrogenism) da kan bas\u0131nc\u0131n\u0131 ins\u00fclin direncinden daha az olmakla birlikte etkilemektedir(58,34,35,36).<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">Polikistik over sendromu olan kad\u0131nlar\u0131n kalp ve damar hastal\u0131klar\u0131 a\u00e7\u0131s\u0131ndan mutlaka de\u011ferlendirilmesi gerekmektedir! <\/mark><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">Bu kad\u0131nlar\u0131n \u00e7ok gen\u00e7 ya\u015flarda adet d\u00fczensizli\u011fi, \u00e7ocuk iste\u011fi, t\u00fcylenme art\u0131\u015f\u0131, sivilce ve sa\u00e7 d\u00f6k\u00fclmesi i\u00e7in kad\u0131n do\u011fum uzman\u0131na ya da cildiye uzman\u0131na ba\u015fvurmalar\u0131 asl\u0131nda y\u00fcksek olan kalp ve damar hastal\u0131klar\u0131 ve metabolik sendrom riskinin erken ya\u015flarda tespit edilmesi a\u00e7\u0131s\u0131ndan \u00f6nemli bir avantaj sa\u011flamaktad\u0131r.<\/mark><\/strong><\/p>\n\n\n\n<p>\u00c7ok gen\u00e7 ya\u015flarda doktora ba\u015fvurmalar\u0131na ra\u011fmen bu kad\u0131nlarda sorun \u00e7\u0131kma ihtimali y\u00fcksek olan kan ya\u011flar\u0131 (trigliserid, kolesterol), ins\u00fclin direnci, bozulmu\u015f \u015feker tolerans\u0131 ve \u015feker hastal\u0131\u011f\u0131 testleri de \u00e7o\u011funlukla yap\u0131lmamaktad\u0131r.<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>Kaynaklar<\/strong><\/p>\n\n\n\n<p>1-Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement.&nbsp;Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute.&nbsp;Circulation. 2005 Oct 25;112(17):2735-52.<\/p>\n\n\n\n<p>2-National Institues of Health. Third Report of the Cholesterol Education Program Expert Panel on Detection, Ealuation, and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01-3670. Bethesda, MD: &nbsp;National Institues of Health. 2001.<\/p>\n\n\n\n<p>3-Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).&nbsp;Balkau B, Charles MA. Diabet Med. 1999 May;16(5):442-3.<\/p>\n\n\n\n<p>4-The metabolic syndrome\u2013a new worldwide definition. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. Lancet. 2005 Sep 24-30;366(9491):1059-62.<\/p>\n\n\n\n<p>5-The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. Reprod Biol Endocrinol. 2014&nbsp;&nbsp;Sep 16;12:89.<\/p>\n\n\n\n<p>6-The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Melo AS, Vieira CS, Romano LG, Ferriani RA, Navarro PA.&nbsp;Reprod Sci. 2011&nbsp;Dec;18(12):1230-6.<\/p>\n\n\n\n<p>7-Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome. Panidis D, Tziomalos K, Macut D, Kandaraki EA, Tsourdi EA, Papadakis E, Katsikis I.&nbsp;Gynecol Endocrinol. 2013&nbsp;Oct;29(10):926-30.<\/p>\n\n\n\n<p>8-Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A.&nbsp;Fertil Steril. 2007&nbsp;Nov;88(5):1389-95.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kalp ve damar hastal\u0131\u011f\u0131&nbsp;(kalp, beyin ve bacaklara oksijen ta\u015f\u0131yan damarlar\u0131n t\u0131kanmas\u0131 veya daralmas\u0131) ihtimalini artt\u0131ran \u00f6zelliklerden bir tanesi kan bas\u0131nc\u0131 y\u00fcksekli\u011fi (hipertansiyon) dir. Bu \u00f6zelliklerden en az 3 tanesi&nbsp;biraraya gelerek metabolik sendromu olu\u015fturmaktad\u0131r(1,2,3,4); 1-Kan bas\u0131nc\u0131 y\u00fcksekli\u011fi (\u2265 130 \/85 mmHg) 2-V\u00fccudun \u00fcst k\u0131sm\u0131nda yani kar\u0131n ve bel b\u00f6lgesinde&nbsp;bulunan ya\u011f miktar\u0131n\u0131n artmas\u0131 (bel \u00e7evresi&nbsp;\u2265 80 cm) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-8460","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/8460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/comments?post=8460"}],"version-history":[{"count":6,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/8460\/revisions"}],"predecessor-version":[{"id":11828,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/8460\/revisions\/11828"}],"wp:attachment":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/media?parent=8460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}